UCB has acquired an antibody (Ab) programme from Wilex' preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the Abs from the programme in any indication outside the field of oncology, while Wilex keeps the rights to develop for oncology indications.
Wilex will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments, as well as royalties.
UCB and Wilex will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these Abs in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to Wilex the relevant data to assist Wilex in oncology.
|Agreement Status:||Updated||Date Announced:||10 Jul 2013|
|Date Last Reported:||10 Jun 2010||Duration:|
|Est Total Value:||Investment To Date:|
|Agreement Type:||Commercialisation Development|
|Generic / Brand Name:|
|Therapeutic Area:||Antineoplastic and Immunomodulating Agents|
|Indication:||Immunological diseases Inflammation|
|Techonology/Field:||Antibody development Drug development|